Table 5.
Therapy and outcome of reported cases of hepatocellular carcinoma associated with autoimmune hepatitis and primary biliary cirrhosis, compared to cases of general hepatocellular carcinoma in Japan
| Clinical status |
Compiled numbers (%) |
P-values |
||||
| HCC patients with AIH (AIH-series) | HCC patients with PBC (PBC-series) | General-HCC patients | AIH-series/General-HCC patients | PBC-series/General-HCC patients | AIH-series/PBC-series | |
| Therapy choices for HCC | Total: 38 | Total: 47 | Total: 17005 | Operation vs CL or TAE P = 0.0481 | RFA, PEIT vs CL or TAE | |
| CL or TAE | 18 (47.4) | 17 (36.2) | 4636 (27.2) | RFA,PEIT,MCT vs | P = 0.0271 | |
| Operation | 8 (21.0) | 16 (34.0) | 5268 (31.0) | CL or TAE | RFA, PEIT vs | |
| RFA, PEIT, MCT | 6 (15.8) | 6 (12.8) | 4890 (28.8) | P = 0.0181 | No therapy | |
| Chemotherapy | 0 (0) | 0 (0) | 765 (4.5) | RFA,PEIT,MCT vs | P = 0.0032 | |
| Others | 0 (0) | 0 (0) | 122 (0.7) | No therapy | ||
| No therapy | 6 (15.8) | 8 (17.0) | 1324 (7.8) | P = 0.0381 | ||
| Clinical outcome | Total: 37 | Total: 49 | Total: 16646 | |||
| Alive | 20 (54.1) | 31 (63.3) | 13946 (83.8) | P < 0.001b | P < 0.001b | P = 0.389 |
| Dead | 17 (45.9) | 18 (36.7) | 2700 (16.2) | |||
| Cause of death | Total: 16 | Total: 18 | Total: 2700 | Neoplastic death vs variceal rupture P = 0.0501 Cancer death vs GI bleeding P = 0.0131 | Neoplastic death vs variceal rupture P = 0.0501 | |
| Liver failure | 8 (50.0) | 8 (44.4) | 581 (21.5) | |||
| HCC rupture | 3 (18.8) | 4 (22.2) | 172 (6.4) | |||
| Variceal rupture | 1 (6.2) | 1 (5.6) | 85 (3.1) | |||
| GI bleeding | 1 (6.2) | 2 (11.1) | 55 (2.0) | |||
| Neoplastic death | 0 (0) | 0 (0) | 1487 (55.1) | |||
| Others | 3 (18.8) | 3 (16.7) | 320 (11.9) | |||
P < 0.01, Statistically significant.
The calculated P-values did not reach statistical significance with Bonferroni correction; without the correction, however, P-values were below 0.05.
The calculated P-values reached statistical significance with Bonferroni correction. HCC: Hepatocellular carcinoma; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; CL: Chemolipiodolization; TAE: Transcatheter arterial embolization; RFA: Radiofrequency ablation therapy; PEIT: Percutaneous ethanol injection therapy; MCT: Microwave coagulation therapy; GI: Gastrointestinal.